Qualigen Therapeutics Inc (QLGN)

$3.47 -0.16 (-4.51%)
Market Cap 2.68M
Revenue (ttm) 0.00
Net Income (ttm) -13.42M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -0.67
Volume 29,300
Avg Vol 69,236
Day's Range N/A - N/A
Shares Out 736,000.00
Stochastic %K 38%
Beta 0.20
Analysts Strong Buy
Price Target $200.00

Latest News on QLGN

Univest Securities, LLC Announces Successful Closing of $5.1 Million Private Placement for Qualigen Therapeutics, Inc. (NASDAQ: QLGN)

Nov 25, 2024, 5:00 PM EST - 5 months ago

Univest Securities, LLC Announces Successful Closing of $5.1 Million Private Placement for Qualigen Therapeutics, Inc. (NASDAQ: QLGN)

Shares Expected to Begin Trading on Split-Adjusted Basis on November 5, 2024

Nov 1, 2024, 9:00 AM EDT - 6 months ago

Shares Expected to Begin Trading on Split-Adjusted Basis on November 5, 2024

Qualigen Therapeutics, Inc. Announces management changes.

Sep 26, 2024, 5:10 PM EDT - 7 months ago

Qualigen Therapeutics, Inc. Announces management changes.

Qualigen Therapeutics, Inc. Received Extension from Nasdaq Hearings Panel

Sep 20, 2024, 9:00 AM EDT - 7 months ago

Qualigen Therapeutics, Inc. Received Extension from Nasdaq Hearings Panel

Univest Securities, LLC Announces Closing of $3.46 Million Registered Direct Offering for its Client Qualigen Therapeutics, Inc. (NASDAQ: QLGN)

Sep 6, 2024, 5:00 PM EDT - 8 months ago

Univest Securities, LLC Announces Closing of $3.46 Million Registered Direct Offering for its Client Qualigen Therapeutics, Inc. (NASDAQ: QLGN)

Qualigen Therapeutics, Inc. Announces Closing of $3.47 Million Public Offering

Sep 6, 2024, 4:30 PM EDT - 8 months ago

Qualigen Therapeutics, Inc. Announces Closing of $3.47 Million Public Offering

Qualigen Therapeutics, Inc. Announces Pricing of $3.46 Million Public Offering

Sep 5, 2024, 9:00 AM EDT - 8 months ago

Qualigen Therapeutics, Inc. Announces Pricing of $3.46 Million Public Offering

Qualigen Therapeutics, Inc. Received Nasdaq Notice of a Delisting Determination

May 30, 2024, 4:00 PM EDT - 11 months ago

Qualigen Therapeutics, Inc. Received Nasdaq Notice of a Delisting Determination

Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting

Apr 10, 2024, 8:00 AM EDT - 1 year ago

Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting

Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting

Apr 9, 2024, 8:00 AM EDT - 1 year ago

Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting

Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023

Nov 14, 2023, 4:30 PM EST - 1 year ago

Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023

Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors

Nov 7, 2023, 8:30 AM EST - 1 year ago

Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors

Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast Cancer

Oct 23, 2023, 8:30 AM EDT - 1 year ago

Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast Cancer

Qualigen Therapeutics Presents Scientific Data on QN-302 at AACR Special Conference: Pancreatic Cancer 2023

Sep 27, 2023, 8:30 AM EDT - 1 year ago

Qualigen Therapeutics Presents Scientific Data on QN-302 at AACR Special Conference: Pancreatic Cancer 2023

Qualigen Therapeutics Partners with TD2 for Phase 1 Clinical Development of QN-302 for the Treatment of Advanced or Metastatic Solid Tumors

Aug 17, 2023, 8:30 AM EDT - 1 year ago

Qualigen Therapeutics Partners with TD2 for Phase 1 Clinical Development of QN-302 for the Treatment of Advanced or Metastatic Solid Tumors

Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending June 30, 2023

Aug 15, 2023, 8:30 AM EDT - 1 year ago

Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending June 30, 2023

Qualigen Therapeutics Announces US FDA IND Clearance to Initiate Phase 1 Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors

Aug 1, 2023, 8:30 AM EDT - 1 year ago

Qualigen Therapeutics Announces US FDA IND Clearance to Initiate Phase 1 Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors

Qualigen Therapeutics Divests FastPack® Diagnostics Business

Jul 24, 2023, 8:15 AM EDT - 1 year ago

Qualigen Therapeutics Divests FastPack® Diagnostics Business

Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

Jun 5, 2023, 8:15 AM EDT - 2 years ago

Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

Qualigen Therapeutics, Inc. Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update

May 2, 2023, 4:30 PM EDT - 2 years ago

Qualigen Therapeutics, Inc. Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update

Qualigen Therapeutics' Pan-RAS Inhibitor Program Highlighted in Two Abstracts at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

May 2, 2023, 8:15 AM EDT - 2 years ago

Qualigen Therapeutics' Pan-RAS Inhibitor Program Highlighted in Two Abstracts at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

Qualigen Therapeutics, Inc. Receives Nasdaq Notice Regarding Delayed Form 10-K Filing

Apr 21, 2023, 5:46 PM EDT - 2 years ago

Qualigen Therapeutics, Inc. Receives Nasdaq Notice Regarding Delayed Form 10-K Filing

Qualigen Therapeutics Announces Four Posters on QN-302 Presented at the American Association of Cancer Research (AACR) 2023 Annual Meeting in Orlando, FL

Apr 18, 2023, 8:45 AM EDT - 2 years ago

Qualigen Therapeutics Announces Four Posters on QN-302 Presented at the American Association of Cancer Research (AACR) 2023 Annual Meeting in Orlando, FL

Qualigen Therapeutics Presents Data On QN-247 in Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, FL

Apr 18, 2023, 7:30 AM EDT - 2 years ago

Qualigen Therapeutics Presents Data On QN-247 in Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, FL

Composition of Matter Patent for QN-302 Granted by United States Patent and Trademark Office

Mar 21, 2023, 8:35 AM EDT - 2 years ago

Composition of Matter Patent for QN-302 Granted by United States Patent and Trademark Office

Qualigen Therapeutics to Present Five Posters at the American Association for Cancer Research Annual Meeting 2023

Mar 15, 2023, 9:05 AM EDT - 2 years ago

Qualigen Therapeutics to Present Five Posters at the American Association for Cancer Research Annual Meeting 2023

Qualigen Therapeutics Presents Data on its RAS Inhibitor Program at the American Association for Cancer Research: Targeting RAS Conference

Mar 9, 2023, 8:30 AM EST - 2 years ago

Qualigen Therapeutics Presents Data on its RAS Inhibitor Program at the American Association for Cancer Research: Targeting RAS Conference

Data on Potential Biomarker for Qualigen Therapeutics' Lead Program QN-302 Published in Peer-Reviewed Journal Molecules

Mar 8, 2023, 8:05 AM EST - 2 years ago

Data on Potential Biomarker for Qualigen Therapeutics' Lead Program QN-302 Published in Peer-Reviewed Journal Molecules

Qualigen Therapeutics Chief Executive Officer Michael Poirier Provides Letter to Stockholders

Feb 1, 2023, 9:05 AM EST - 2 years ago

Qualigen Therapeutics Chief Executive Officer Michael Poirier Provides Letter to Stockholders

Qualigen Therapeutics Initiates Good Laboratory Practice (GLP) Toxicology Studies on QN-302

Jan 24, 2023, 9:00 AM EST - 2 years ago

Qualigen Therapeutics Initiates Good Laboratory Practice (GLP) Toxicology Studies on QN-302

Qualigen Therapeutics Promotes Benedict M. Abugan to Vice President, Head of Diagnostics and Corporate Communications

Jan 23, 2023, 9:02 AM EST - 2 years ago

Qualigen Therapeutics Promotes Benedict M. Abugan to Vice President, Head of Diagnostics and Corporate Communications

Qualigen Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for QN-302, a G-Quadruplex (G4) Transcription Inhibitor for the Intended Indication of Pancreatic Cancer

Jan 10, 2023, 9:00 AM EST - 2 years ago

Qualigen Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for QN-302, a G-Quadruplex (G4) Transcription Inhibitor for the Intended Indication of Pancreatic Cancer

Qualigen Therapeutics Provides Update on Developments at NanoSynex; Significant Progress Reported on Infectious Disease Diagnostic Platform

Jan 5, 2023, 9:00 AM EST - 2 years ago

Qualigen Therapeutics Provides Update on Developments at NanoSynex; Significant Progress Reported on Infectious Disease Diagnostic Platform

Qualigen Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule

Dec 12, 2022, 8:30 AM EST - 2 years ago

Qualigen Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule

Qualigen Therapeutics Announces Pre-IND Feedback from U.S. Food and Drug Administration Regarding QN-302 for the Treatment of G4-Targeted Advanced Solid Tumors

Dec 7, 2022, 9:10 AM EST - 2 years ago

Qualigen Therapeutics Announces Pre-IND Feedback from U.S. Food and Drug Administration Regarding QN-302 for the Treatment of G4-Targeted Advanced Solid Tumors

Qualigen Therapeutics, Inc. Announces 1-for-10 Reverse Stock Split

Nov 22, 2022, 9:00 AM EST - 2 years ago

Qualigen Therapeutics, Inc. Announces 1-for-10 Reverse Stock Split

Qualigen Therapeutics, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Nov 15, 2022, 7:30 AM EST - 2 years ago

Qualigen Therapeutics, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Qualigen Therapeutics Announces Two Posters of Its RAS-Targeted Inhibitor Program at the National Cancer Institute

Oct 19, 2022, 9:00 AM EDT - 2 years ago

Qualigen Therapeutics Announces Two Posters of Its RAS-Targeted Inhibitor Program at the National Cancer Institute

Qualigen Therapeutics to Present at LD Micro Main Event XV

Oct 18, 2022, 9:00 AM EDT - 2 years ago

Qualigen Therapeutics to Present at LD Micro Main Event XV

Qualigen Therapeutics Presents Data on QN-302 at AACR's Pancreatic Cancer Meeting

Sep 14, 2022, 5:02 PM EDT - 2 years ago

Qualigen Therapeutics Presents Data on QN-302 at AACR's Pancreatic Cancer Meeting

Qualigen Therapeutics Announces Formation and First Meeting of QN-302 Scientific Advisory Board

Aug 18, 2022, 9:15 AM EDT - 2 years ago

Qualigen Therapeutics Announces Formation and First Meeting of QN-302 Scientific Advisory Board

Qualigen Therapeutics, Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Aug 16, 2022, 7:30 AM EDT - 2 years ago

Qualigen Therapeutics, Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Qualigen Therapeutics Reports Positive QN-247 Readout in Triple Negative Breast Cancer in Vivo Model

Aug 1, 2022, 8:30 AM EDT - 2 years ago

Qualigen Therapeutics Reports Positive QN-247 Readout in Triple Negative Breast Cancer in Vivo Model

Qualigen Therapeutics Announces Partnership with Hande Sciences To Scale-Up Manufacturing To Support IND-Enabling Studies for QN-302

Jul 6, 2022, 9:00 AM EDT - 3 years ago

Qualigen Therapeutics Announces Partnership with Hande Sciences To Scale-Up Manufacturing To Support IND-Enabling Studies for QN-302

Qualigen Therapeutics to Present at BIO International Convention

Jun 14, 2022, 9:00 AM EDT - 3 years ago

Qualigen Therapeutics to Present at BIO International Convention

Qualigen Therapeutics Announces IND-Enabling Studies to Advance Lead Program QN-302 Toward Clinical Trials

Jun 7, 2022, 9:04 AM EDT - 3 years ago

Qualigen Therapeutics Announces IND-Enabling Studies to Advance Lead Program QN-302 Toward Clinical Trials

Qualigen Therapeutics Acquires Majority Stake in Infectious Disease Diagnostics Technology Company NanoSynex

Jun 2, 2022, 9:00 AM EDT - 3 years ago

Qualigen Therapeutics Acquires Majority Stake in Infectious Disease Diagnostics Technology Company NanoSynex

Qualigen Therapeutics' Pan-RAS Inhibitor Featured in Two Abstracts at American Society for Clinical Oncology (ASCO) 2022 Annual Meeting

May 26, 2022, 9:15 AM EDT - 3 years ago

Qualigen Therapeutics' Pan-RAS Inhibitor Featured in Two Abstracts at American Society for Clinical Oncology (ASCO) 2022 Annual Meeting

Qualigen Therapeutics to Present at the H.C. Wainwright Global Investment Conference

May 20, 2022, 9:15 AM EDT - 3 years ago

Qualigen Therapeutics to Present at the H.C. Wainwright Global Investment Conference

Qualigen Therapeutics, Inc. Provides Corporate Update and Reports First Quarter 2022 Financial Results

May 13, 2022, 6:00 AM EDT - 3 years ago

Qualigen Therapeutics, Inc. Provides Corporate Update and Reports First Quarter 2022 Financial Results